2025-10-04 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the provided information.

**Report on TG Therapeutics Inc. (TGTX)**

TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO)**

*   **TGTX Cumulative Return:** 93.65%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Divergence:** -5.1
*   **Relative Divergence:** 23.6

**Analysis:** TGTX has underperformed the S&P 500 by 5.1% over the tracked period. The relative divergence of 23.6 indicates that TGTX's performance is in the lower quartile of its historical divergence range compared to the S&P 500.

**Alpha/Beta Analysis:**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |   -5   |  73.5 |   -33   |   -0   |      1.3 |
| 2016-2018  |  -12   |  73.5 |   -27   |   -0   |      0.7 |
| 2017-2019  |   74   |  74.1 |    52   |    0   |      1.8 |
| 2018-2020  |  316   |  74.1 |   293   |    0.1 |      8.2 |
| 2019-2021  |  124   |  74.1 |    78   |    0.3 |      3   |
| 2020-2022  |  -71   |  77.8 |   -71   |   -0   |      1.9 |
| 2021-2023  | -284   |  77.8 |  -285   |   -1.1 |      2.7 |
| 2022-2024  |   56   |  77.8 |    36   |   -1   |      4.8 |
| 2023-2025  |   94   |  74.8 |    31   |   -0.1 |      5.8 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows significant volatility over different periods, with some periods showing substantial growth (e.g., 2018-2020) and others showing significant decline (e.g., 2021-2023).
*   **MDD:** The Maximum Drawdown is consistently high, indicating substantial risk.
*   **Alpha:** The Alpha values are also highly variable, showing periods of significant outperformance and underperformance relative to the market.
*   **Beta:** Beta values are generally low, indicating a low correlation with the market. However, the negative Beta values in recent years (2021-2025) suggest an inverse relationship, meaning the stock tends to move in the opposite direction of the market.

**2. Recent Stock Price Movements**

*   **Current Price:** 36.71
*   **Last Market Change:** price increase of 0.12
*   **5-Day Moving Average:** 36.49
*   **20-Day Moving Average:** 34.01
*   **60-Day Moving Average:** 32.73

**Analysis:** The current price is above all moving averages, indicating a recent upward trend. The 5-day moving average is above the 20-day and 60-day, suggesting short-term momentum is strong. The increase in price compared to the previous close supports this upward trend.

**3. Indicators and Signals**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 80.99 (Overbought)
*   **PPO:** 0.79
*   **Hybrid Signal:** Buy 100% of cash (27 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00)
*   **Delta_Previous_Relative_Divergence:** 1.8 (Positive - Short-term Increase)
*   **Expected Return (%):** -93.4%

**Analysis:**

*   The MRI suggests that the market conditions are currently favorable for investment.
*   The RSI is in overbought territory, suggesting a potential pullback might be due.
*   The positive change in relative divergence supports the recent upward price movement.
*   The Hybrid Signal indicates a strong buy recommendation.
*   The very negative expected return is a significant concern, suggesting long-term underperformance relative to the S&P 500 if a buy-and-hold strategy is adopted.
*   The slight positive change in the recent market (price increase of 0.12 from the previous close) doesn't point to any major volatility but confirms the upward trend.

**4. Recent News & Significant Events**

*   **Positive Clinical Data:**  Multiple news items highlight positive 6-year data for Briumvi in multiple sclerosis, showing a high percentage of patients free from disease progression.
*   **Analyst Upgrade:** B. Riley raised its price target on TG Therapeutics to $55, maintaining a Buy rating.
*   **Insider Selling:** An insider sold shares worth $672,268.

**Analysis:** Positive clinical trial results are generally a strong catalyst for biotech stocks. The analyst upgrade further reinforces positive sentiment. However, insider selling, while not always a negative indicator, should be noted and considered in the context of the other information.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.75)
*   **Target Price:** $40.83 (Avg) / $55 (High) / $11 (Low)

**Analysis:** Analyst consensus is positive with a "Buy" rating. The average target price is above the current price, suggesting upside potential. However, the wide range between the high and low target prices indicates uncertainty.

**5. Recent Earnings Analysis**

| 날짜       |   EPS | 매출     |
|:-----------|------:|:---------|
| 2025-08-08 |  0.19 | 0.14 B$ |
| 2025-05-09 |  0.03 | 0.12 B$ |
| 2024-11-07 |  0.03 | 0.08 B$ |
| 2024-08-09 |  0.05 | 0.07 B$ |
| 2025-08-08 |  0.05 | 0.07 B$ |

**Analysis:** The most recent EPS and revenue figures show improvement compared to the previous periods, indicating positive momentum.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin   |
|:-------------|:-----------|:----------------|
| 2025-06-30   | \$0.14B    | 86.58%          |
| 2025-03-31   | \$0.12B    | 87.14%          |
| 2024-12-31   | \$0.11B    | 85.77%          |
| 2024-09-30   | \$0.08B    | 88.86%          |
| 2024-06-30   | \$0.07B    | 88.70%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE        |
|:-------------|:-----------|:-----------|
| 2025-06-30   | \$0.28B    | 10.20%     |
| 2025-03-31   | \$0.24B    | 2.13%      |
| 2024-12-31   | \$0.22B    | 10.49%     |
| 2024-09-30   | \$0.19B    | 2.02%      |
| 2024-06-30   | \$0.18B    | 3.87%      |

**Analysis:**

*   **Revenue:** Revenue is growing steadily over the recent quarters.
*   **Profit Margin:** The profit margins are exceptionally high, indicating strong pricing power or efficient cost management.
*   **Equity:** Equity is increasing, reflecting the company's growth and profitability.
*   **ROE:** The Return on Equity fluctuates, but the most recent quarter shows a strong ROE of 10.20%.

**7. Overall Summary**

TGTX shows a mixed picture.

*   **Positives:**
    *   Positive clinical trial data for Briumvi.
    *   Analyst upgrades and positive consensus.
    *   Strong recent revenue and profit margin growth.
    *   Increasing equity and positive ROE.
    *   Short-term upward price momentum.
    *   High MRI indicating favorable investment environment.

*   **Negatives:**
    *   Underperformance compared to the S&P 500.
    *   Very high MDD and volatile Alpha values.
    *   Overbought RSI, suggesting potential pullback.
    *   Very negative long-term expected return.
    *   Insider selling.
    *   Low Beta values, suggesting an inverse relationship, meaning the stock tends to move in the opposite direction of the market.

**Conclusion:**

TGTX presents a speculative opportunity. The positive clinical data and analyst outlook suggest potential upside, but the stock's historical volatility, recent underperformance, and negative long-term expected return warrant caution. The high RSI suggests the stock may be overbought in the short term. The insider selling is a point to consider. The Hybrid Signal is also taken into account, suggesting that a buy can be made with the cash on hand to take advantage of the potential upswing.
